Package Leaflet: Information for the User
Abiraterona SUN 500 mg film-coated tablets EFG
abiraterone acetate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Abiraterona SUN contains the active substance abiraterone acetate. It is used for the treatment of prostate cancer in adult men that has spread to other parts of the body. Abiraterone makes your body stop producing testosterone; this can slow down the growth of prostate cancer.
When abiraterone is prescribed in the early stages of the disease and there is still a response to hormonal treatment, it is used together with a treatment to reduce testosterone (androgen deprivation therapy).
When taking this medicine, your doctor will also prescribe another medicine called prednisone or prednisolone, to reduce the risk of you experiencing high blood pressure, accumulating too much water in your body (fluid retention), or low levels of a chemical called potassium in your blood.
Do not take Abiraterona SUN
Do not take this medicine if any of the above applies to you. If you are not sure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor or pharmacist before starting to take this medicine:
Tell your doctor if you have been told you have any heart or blood vessel disorder, including heart rhythm problems (arrhythmia), or if you are being treated with medicines for these disorders.
Tell your doctor if you have yellowing of the skin or eyes, dark urine, or severe nausea or vomiting, as these may be signs or symptoms of liver problems. Rarely, liver failure (called acute hepatic failure) may occur, which can be life-threatening.
A decrease in the number of red blood cells in your blood, reduced sexual desire (libido), and cases of muscle weakness and/or muscle pain may occur.
Abiraterone should not be taken in combination with Ra-223 due to a possible increased risk of bone fracture or death.
If you plan to take Ra-223 after treatment with abiraterone and prednisone/prednisolone, you should wait 5 days before starting Ra-223 treatment.
If you are not sure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.
Blood tests
Abiraterone may affect your liver even if you do not have any symptoms. While taking this medicine, your doctor will perform regular blood tests to check for any effect on your liver.
Children and adolescents
This medicine should not be used in children or adolescents. If a child or adolescent accidentally takes abiraterone, they should go to the hospital immediately and bring this leaflet to show the emergency doctor.
Other medicines and abiraterone
Consult your doctor or pharmacist before taking any other medicine.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is important because abiraterone may increase the effects of a number of medicines, including heart medicines, sedatives, some diabetes medicines, herbal medicines (e.g., St. John's Wort), and others. Your doctor may consider changing the dose of these medicines. Additionally, some medicines may increase or decrease the effects of abiraterone. This may lead to side effects or abiraterone may not work as well as it should.
Androgen deprivation therapy may increase the risk of heart rhythm problems. Tell your doctor if you are being treated with medicines
Consult your doctor if you are taking any of the above medicines.
Abiraterone with food
Pregnancy and breastfeeding
Abiraterone is not indicated in women.
Driving and using machines
It is unlikely that this medicine will affect your ability to drive or use tools or machines.
Abiraterona SUN contains lactose and sodium
This medicine contains lactose (a type of sugar). If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
This medicine also contains 22 mg of sodium (the main component of table salt/cooking salt) in each daily dose of 2 tablets. This is equivalent to 1.1% of the maximum recommended daily intake of sodium for an adult.
Follow exactly the instructions of administration of this medicine given by your doctor. If you are not sure, consult your doctor or pharmacist again.
How much to take
The recommended dose is 1,000 mg (two tablets) once a day.
How to take this medicine
Your doctor may also prescribe other medicines while you are taking abiraterone and prednisone or prednisolone.
If you take more Abiraterona SUN than you should
If you take more than you should, consult your doctor or go to the hospital immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Abiraterona SUN
If you stop taking Abiraterona SUN
Do not stop taking abiraterone or prednisone or prednisolone unless your doctor tells you to.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Stop taking abiraterone and consult your doctor immediately if you experience any of the following:
These may be signs of low potassium levels in your blood.
Other side effects are:
Very common(may affect more than 1 in 10 people):
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Frequency not known(cannot be estimated from the available data):
Bone density loss may occur in men receiving treatment for prostate cancer. Abiraterone in combination with prednisone or prednisolone may increase this bone density loss.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines Agency (AEMPS) through the website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister label after EXP. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Abiraterona SUN
Appearance and packaging
Film-coated tablets are purple, oval, biconvex (20.03 mm long and 10.02 mm wide), and engraved with “S500” on one side.
Abiraterona SUN is available in blisters.
Package sizes: boxes with PVC/PE/PVdC/Al blisters of 56, 60, or 120 film-coated tablets and boxes with PVC/PE/PVdC/Al unit-dose blisters of 56 x 1, 60 x 1, or 120 x 1 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorisation holder
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132 JH Hoofddorp
Netherlands
Manufacturer
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132 JH Hoofddorp
Netherlands
Or
Terapia S.A.
124 Fabricii Street
400632, Cluj-Napoca
Romania
For further information about this medicine, please contact the local representative of the marketing authorisation holder:
Sun Pharma Laboratorios, S.L.
Rambla de Catalunya 53-55
08007 Barcelona
Spain
Phone: +34 93 342 78 90
This medicine is authorised in the Member States of the European Economic Area under the following names:
Germany: Abirateron SUN 500 mg Filmtabletten
France: Abiratérone SUN 500 mg comprimé pelliculé
Italy: Abiraterone SUN
Poland: Abirateron SUN
Romania: Abirateronă SUN 500 mg comprimate filmate
Spain: Abiraterona SUN 500mg comprimidos recubiertos con película EFG
Date of last revision of this leaflet: July 2022
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).